A bivalent Mpox nanoparticle vaccine induces robust immune response and provides long-lasting protection against vaccinia virus challenge.

ABSTRACT: The 2022 and 2024 monkeypox (mpox) outbreak highlighted the urgent need for effective, durable, and safe vaccines. In addition to the traditional smallpox vaccines that could bring cross-protection against mpox, mRNA and protein-subunit mpox vaccines were extensively studied after the outbreak of mpox. In this study, we engineered monkeypox virus (MPXV) nanoparticle vaccines by conjugating the M1R and A35R, two well-characterized protective antigens to the mi3 nanoparticle using the SpyTag-SpyCatcher system, generating mi3-M1R and mi3-A35R constructs. An equimolar mixture of mi3-M1R and mi3-A35R formed a bivalent MPXV vaccine candidate, termed mi3-AM. When administered intraperitoneally with the Mn adjuvant, the mi3-AM vaccine induced robust humoral and antigen-specific cellular immune res

SUBMITTER: Wang Y 

PROVIDER: S-EPMC12305883 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature